Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia

BACKGROUND: Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of morbidity and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine storm. METHODS: We treated 89 hospitalized patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C...

Descripción completa

Detalles Bibliográficos
Autores principales: Fomina, Daria S., Lysenko, Mar'yana A., Beloglazova, Irina P., Mutovina, Zinaida Yu., Poteshkina, Nataliya G., Samsonova, Inna V., Kruglova, Tat'yana S., Chernov, Anton A., Karaulov, Alexander V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pathogens and Immunity 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556411/
https://www.ncbi.nlm.nih.gov/pubmed/33089038
http://dx.doi.org/10.20411/pai.v5i1.392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556411/
https://www.ncbi.nlm.nih.gov/pubmed/33089038
http://dx.doi.org/10.20411/pai.v5i1.392

Ejemplares similares